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IMPORTANCE Failure of bone fracture healing occurs in 5% to 10% of all patients. Nonunion
risk is associated with the severity of injury and with the surgical treatment technique, yet
progression to nonunion is not fully explained by these risk factors.
OBJECTIVE To test a hypothesis that fracture characteristics and patient-related risk factors
assessable by the clinician at patient presentation can indicate the probability of fracture
nonunion.
DESIGN, SETTING, AND PARTICIPANTS An inception cohort study in a large payer database of
patients with fracture in the United States was conducted using patient-level health claims for
medical and drug expenses compiled for approximately 90.1 million patients in calendar year
2011. The final database collated demographic descriptors, treatment procedures as per
Current Procedural Terminology codes; comorbidities as per International Classification of
Diseases, Ninth Revision codes; and drug prescriptions as per National Drug Code Directory
codes. Logistic regression was used to calculate odds ratios (ORs) for variables associated
with nonunion. Data analysis was performed from January 1, 2011, to December 31, 2012,
EXPOSURES Continuous enrollment in the database was required for 12 months after fracture
to allow sufficient time to capture a nonunion diagnosis.
RESULTS The final analysis of 309 330 fractures in 18 bones included 178 952 women
(57.9%); mean (SD) age was 44.48 (13.68) years. The nonunion rate was 4.9%. Elevated
nonunion risk was associated with severe fracture (eg, open fracture, multiple fractures), high
bodymass index, smoking, and alcoholism. Women experiencedmore fractures, but men
weremore prone to nonunion. The nonunion rate also varied with fracture location:
scaphoid, tibia plus fibula, and femur were most likely to be nonunion. The ORs for nonunion
fractures were significantly increased for risk factors, including number of fractures
(OR, 2.65; 95% CI, 2.34-2.99), use of nonsteroidal anti-inflammatory drugs plus opioids (OR,
1.84; 95% CI, 1.73-1.95), operative treatment (OR, 1.78; 95% CI, 1.69-1.86), open fracture (OR,
1.66; 95% CI, 1.55-1.77), anticoagulant use (OR, 1.58; 95% CI, 1.51-1.66), osteoarthritis with
rheumatoid arthritis (OR, 1.58; 95% CI, 1.38-1.82), anticonvulsant use with benzodiazepines
(OR, 1.49; 95% CI, 1.36-1.62), opioid use (OR, 1.43; 95% CI, 1.34-1.52), diabetes (OR, 1.40;
95% CI, 1.21-1.61), high-energy injury (OR, 1.38; 95% CI, 1.27-1.49), anticonvulsant use (OR,
1.37; 95% CI, 1.31-1.43), osteoporosis (OR, 1.24; 95% CI, 1.14-1.34), male gender (OR, 1.21; 95%
CI, 1.16-1.25), insulin use (OR, 1.21; 95% CI, 1.10-1.31), smoking (OR, 1.20; 95% CI, 1.14-1.26),
benzodiazepine use (OR, 1.20; 95% CI, 1.10-1.31), obesity (OR, 1.19; 95% CI, 1.12-1.25),
antibiotic use (OR, 1.17; 95% CI, 1.13-1.21), osteoporosis medication use (OR, 1.17; 95% CI,
1.08-1.26), vitamin D deficiency (OR, 1.14; 95% CI, 1.05-1.22), diuretic use (OR, 1.13; 95% CI,
1.07-1.18), and renal insufficiency (OR, 1.11; 95% CI, 1.04-1.17) (multivariate P < .001 for all).
CONCLUSIONS AND RELEVANCE The probability of fracture nonunion can be based on
patient-specific risk factors at presentation. Risk of nonunion is a function of fracture severity,
fracture location, disease comorbidity, andmedication use.
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T he rate of fracture nonunion is estimated to be be-tween 5%1 and 10%,2 and the rate of nonunionmay beincreasing as the survival rate for patients with severe
injuries improves.3 The risk of nonunion is related to the se-
verity of injury resulting in fracture,4 and many randomized
clinical trials5 have shown that variations in nonunion rates
areassociatedwithdifferentsurgical treatments.However,pro-
gression to nonunion is not fully explained by these factors
alone.6Determinationof theprobability for andpotentialmiti-
gation of nonunion risk is an important clinical objective be-
causepatientswithnonunioncanexpectmore long-termpain,
physical disability,mentalhealthproblems, andmedical treat-
ment costs as well as a slower return to normal work
productivity.7 Herein, we describe the epidemiology of frac-
ture nonunion in adults, with a focus on information avail-
able to the clinician at patient presentation. We hypothesize
that the interplay between a patient’s physiologic risk factors
and fracture characteristics increases the risk of fracture
nonunion.5 We tested this hypothesis in a large payer data-
base of patients with fracture in the United States.8
Methods
Database
Truven Health Analytics (Durham, North Carolina) compiled
patient-level health claims data for medical and drug
expenses, together with laboratory test results, hospital dis-
charge information, and death data on 90.1 million
patients.9 Data were submitted by hospitals, managed care
organizations, Medicare and Medicaid programs, and
approximately 300 large corporations in exchange for bench-
mark reports.9 This study was approved and exempted from
the need for informed consent by the institutional review
board of Duke University Medical Center because patient
data were deidentified.
The final database contained 1 row per unique fracture,
with comma-separated values for patient variables. Variables
included patient demographics, treatment procedures as per
theCurrentProcedural Terminology codes; disease comorbidi-
ties asper the InternationalClassificationofDiseases,NinthRe-
vision (ICD-9) codes; and drug prescriptions as per National
DrugCodeDirectory (https://www.accessdata.fda.gov/scripts
/cder/ndc/) codes.
Study Design
Study inclusionwas limited topatientswithacodedbone frac-
ture in calendar year 2011. Patients were excluded if they had
less than 12months of continuous enrollment following frac-
ture so as to capture all coded nonunions.
Fractures were identified based on 5-digit ICD-9 codes.
Rule-out codes were not counted; such codes are used to or-
der radiography in some patients who may not have a frac-
ture. In addition, codes with an unspecified character string
in the definition were not used because such codes are re-
placed with a specific code defining the location of the frac-
ture. Nonunion was determined by the presence of either a
nonunion code or a code for prescription use of an electrical
bone stimulation device since such devices are used to treat
nonunion. Patients who used low-intensity pulsed ultra-
sounddevices for a fresh fracturewere excludedbecause this
prescription device may increase the healing rate for bone.
Disease comorbidities were identified using ICD-9 pri-
mary disease codes. Secondary conditions arising from a
chronic disease condition (eg, diabetic retinopathy) were not
used as proxies for the primary disease because of the risk of
double counting. Thus, our analysis would not identify pa-
tientswithdiabetes diagnosedbefore 2011, althoughmedica-
tions used to treat diabetes would be captured. Medications
were identified using National Drug Code Directory codes,
which are for oral medications purchased in a retail phar-
macy. Such codes contain a range of medications; the opioid
class contains analgesics but can also contain opioid agonists
used to treat addiction.Medicationswere assumed to be part
of long-termtherapy,with theexceptionof antibiotics, throm-
bolytics, analgesics, and corticosteroids.
Analysis focused on the cohort of patients aged 18 to 63
years at the time of the fracture. This age range was chosen
because skeletal maturity is achieved by approximately 18
years.10 Patients younger than 18 years were abundant in the
database, but their healing rate was high, so it was less com-
pelling to identify risk factors for those who failed to heal.
Patients older than 63 years were excluded because the
requirement for 12 months of continuous enrollment created
an artifact as patients transitioned to Medicare and no longer
appeared in the database. Older individuals were also
excluded because only some purchase Medicare supplemen-
tal coverage and thus are not representative of other Medi-
care patients.
Analytic Strategy
Ouroverall hypothesiswas that theprobabilityof fracturenon-
union can be determined with the use of risk factors derived
from patient demographics, using Current Procedural Termi-
nology, ICD-9, and National Drug Code Directory codes. Pos-
sible risk factors for nonunion were identified in a literature
search,5 with a focus on risk factors likely to be of concern to
orthopedic surgeons. We requested information on 257 po-
tential nonunion risk factors, including fracture type, frac-
ture cause, patient demographics, andmedicationuse.We fo-
cused on 18 bones most frequently fractured. An operative
Key Points
Question Which patient-specific risk factors other than injury
severity increase risk of nonunion of fractures?
Findings In an inception cohort study of a payer database in
which 309 330 fractures in 18 bones were analyzed, only 5
patient-specific risk factors significantly increased the risk of
nonunionmore than 50% across all bones: multiple concurrent
fractures, prescription nonsteroidal anti-inflammatory drug and
opioid use, open fracture, anticoagulant use, and osteoarthritis
with rheumatoid arthritis.
Meaning The probability of fracture nonunion can be determined
from patient-specific risk factors at presentation.
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treatment variablewas defined for patientswho received any
fracture surgeryandwecompared themwithpatientswhodid
notundergosurgery. Statistical analyseswereperformedusing
SAS, version 9.4 (SAS Institute Inc). The critical value for sig-
nificance was set at P < .05.
Because so many variables were available for each pa-
tient, itwas important to groupvariables intomanageable cat-
egories. Ultimately, datawere pooled to obtain 45 variables of
interest (eAppendix in the Supplement). For example, pa-
tientshadasmanyas 15separate fractures,butwebinnedthem
into a smaller number of categories for analysis (eg, 1-2 frac-
tures, 3-5 fractures, and≥6 fractures).Multivariate logistic re-
gression was used to control for correlations among the vari-
ous risk factors.
We did not adjust for multiple comparisons because
showing 95% CIs for each odds ratio (OR) achieves the same
end. Furthermore, an OR significant at P < .001 is comparable
to an OR significant at P = .05 that has been Bonferroni cor-
rected for 50 comparisons. Correcting for additional compari-
sons would be likely to lead to type II (false-negative) errors.
In an exploratory context such as this, P values should be
interpreted as a measure of statistical evidence rather than a
test of hypothesis.
Validation
In parallel to the logistic regression analysis, we also con-
ducted random forest decision treemodeling using the same
covariates.11 The random forest method is invariant to inter-
actionsandtermsofhigherdimension,suchasquadratic terms.
The random forestmethod generally performsbetter than re-
gressionmethods but, unlike regression analysis, is harder to
interpret.Wecompared themethodsusing theC statistic (area
under the receiver operating characteristic curve) and found
that the models were substantially equivalent; the C statistic
of the random forest model was only slightly larger than the
Cstatistic of the logistic regressionmodel, differing in the third
or fourthdecimal place.Weelected to report only themain ef-
fects logistics regressionmodel herein.Nonunion rates for in-
dividual bones were also compared with those in the litera-
ture. Data analysis was performed from January 1, 2011, to
December 31, 2012.
Results
A flowchart (eFigure in the Supplement) shows how the pa-
tient sample was assembled. There were 309330 fractures in
patients ranging from18 to63years (mean [SD],44.48 [13.68]),
or approximately 6725 patients in each of the 46 age classes.
The overall nonunion rate was 4.9% (Table 1), with substan-
tial variation frombone to bone. Themetatarsalwas themost
frequently fractured bone, with a nonunion rate of 5.7%. The
lowest nonunion rates were for themetacarpal (1.5%) and ra-
dius (2.1%) bones. The highest nonunion rates were for the
scaphoid (15.5%), followed by the tibia and fibula (14%) and
femur (13.9%). These were the only bones for which the non-
unionratewasgreater than10%. If4.9%ofallpatientshadnon-
union fractures (Table 1), then there were approximately 330
nonunionpatients per age class. This relatively small number
of nonunion fractures per age class could potentially result in
uncertainty in estimatingnonunion rates as a function of age.
There were clear demographic differences between pa-
tients who healed and those who failed to heal (Table 1).
Womenhadmore fractures, butmen had a higher proportion
of nonunions. Open fractures represented 3.9% of all frac-
tures, but 10.9% of open fractures were nonunion and 4.7%
of closed fractures were nonunion. Multiple fractures were
more likely result innonunion;nonunion frequencywas4.4%
in patients with 1 fracture but 24% among patients with 7 or
more fractures.
MultivariateanalysisdeterminedtheORsofnonunionwith
comorbiddiseasewhenadjusted forother risk factors (Table2).
Table 1. Demographic Summary of AdultsWith andWithout
Nonunion Fracture
Characteristic
No. (%)
Total Nonunion
Fractures 309 330 (100) 15 249 (4.9)
Patient age at fracture, y
18-29 59 451 (19.2) 2704 (4.5)
30-39 44 353 (14.3) 2128 (4.8)
40-49 64 779 (20.9) 3573 (5.5)
50-63 140 747 (45.5) 6844 (4.9)
Sex
Male 130 378 (42.1) 7010 (5.4)
Female 178 952 (57.9) 8239 (4.6)
BMI
<25.0 285 611 (92.3) 13 412 (4.7)
25.0-29.9 1570 (0.5) 74 (4.7)
30.0-39.9 13 050 (4.2) 941 (7.2)
≥40.0 9099 (2.9) 822 (9)
Bone type
Long 166 377 (53.8) 8042 (4.8)
Other 142 953 (46.2) 7207 (5)
Fracture type
Closed 297 172 (96.1) 13 918 (4.7)
Open 12 158 (3.9) 1331 (10.9)
No. of fractures
1 256 367 (82.9) 11 389 (4.4)
2 36 818 (11.9) 2069 (5.6)
3 9053 (2.9) 744 (8.2)
4 3411 (1.1) 359 (10.5)
5 1675 (0.5) 237 (14.1)
6 929 (0.3) 192 (20.7)
≥7 1077 (0.3) 259 (24.0)
Past or current smoker
No 277 720 (89.8) 12 936 (4.7)
Yes 31 610 (10.2) 2313 (7.3)
Diagnosed alcoholism
No 303 714 (98.2) 14 831 (4.9)
Yes 5616 (1.8) 418 (7.4)
Abbreviation: BMI, bodymass index (calculated as weight in kilograms divided
by height in meters squared).
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Multivariate evaluation of fractures associated with comor-
bidities (Table2) indicatedthat3 risk factors (osteoarthritis [OR,
1.45; 95%CI, 1.39-1.52], osteoarthritiswith rheumatoid arthri-
tis [OR, 1.58; 95%CI, 1.38-1.82], and type 1 diabetes [OR, 1.40;
95% CI, 1.21-1.61]) increased the odds of nonunion by at least
40%.Oddsratios for individualnonunionrisk factorsweregen-
erally small, with 13 of 16 multivariate ORs less than 1.40
(Table 2). Two risk factorswere inversely associatedwithnon-
union (OR,<1): cardiovasculardisease (OR,0.94;95%CI,0.90-
0.98) and allergy (OR, 0.90; 95%CI, 0.86-0.93) (Table 2). The
number of risk factors and the complex interactions possible
between risk factors may explain the absence ofmultivariate
ORs higher than 1.58 (Table 2).
Use of certain medications increased the nonunion risk
(Table 3). After controlling for confoundingvariables, themost
powerful risk factor was use of nonsteroidal anti-inflamma-
torydrugs (NSAIDs) and opioids (multivariateOR, 1.84;95%CI,
1.73-1.95). Other pain medications, such as opioids alone, and
anticonvulsants,withorwithoutbenzodiazepines,weremod-
erately strongpositive risk factors,whereas antidiabeticsother
than insulin (OR, 0.92; 95%CI, 0.86-0.99) and oral contracep-
tives (OR, 0.88; 95% CI, 0.81-0.95) were inversely associated
with nonunion.
NonunionORswere significantly increased formany risk
factors (Table 4 and Table 5), including number of fractures
(OR, 2.65; 95% CI, 2.34-2.99), use of prescription analgesics
(NSAIDs and opioids; OR, 1.84; 95% CI, 1.73-1.95), operative
treatment (OR, 1.78;95%CI, 1.69-1.86), open fracture (OR, 1.66;
95% CI, 1.55-1.77), anticoagulant use (OR, 1.58; 95% CI, 1.51-
1.66), osteoarthritis with rheumatoid arthritis (OR, 1.58; 95%
CI, 1.38-1.82), anticonvulsant use with benzodiazepines (OR,
1.49; 95% CI, 1.36-1.62), opioid use (OR, 1.43; 95% CI, 1.34-
1.52), type 1 diabetes (OR, 1.40; 95% CI, 1.21-1.61), high-
energy injury (OR, 1.38; 95%CI, 1.27-1.49), osteoporosis (1.24;
95%CI, 1.14-1.34),male gender (OR, 1.21; 95%CI, 1.16-1.25), in-
sulinuse (OR, 1.21; 95%CI, 1.10-1.31), diagnosed smoking (OR,
1.20; 95% CI, 1.14-1.26), diagnosed obesity (OR, 1.19; 95% CI,
1.12-1.25), antibiotic use (OR, 1.17; 95% CI, 1.13-1.21), osteopo-
rosis medication use (OR, 1.17; 95% CI, 1.08-1.26), diagnosed
vitaminDdeficiency (OR, 1.14; 95%CI, 1.05-1.22), diuretic use
(OR, 1.13; 95% CI, 1.07-1.18), and renal insufficiency (OR, 1.11;
95% CI, 1.04-1.17) (all, multivariate P < .001).
Relatively fewrisk factorsaffectedmultiplebones (Tables4
and 5). The need for operative treatment was associated with
nonunion in 15 bones, anticoagulant use was associated with
nonunion in 14 bones, use of analgesics (NSAIDs and opioids)
affected12bones, andosteoarthritis anduseofanticonvulsants
each affected 11 bones. Overall, the largest risk factor for non-
unionwasthenumberof fractures (OR,2.65;95%CI,2.34-2.99).
A limited number of putative risk factors were inversely
correlatedwithnonunion (Tables 4 and5), includingoral con-
traceptiveuse (OR,0.88;95%CI,0.81-0.95), allergy (OR,0.90;
95%CI,0.86-0.93), andage (OR,0.97;95%CI,0.95-0.98); each
wasapparentlyprotective inat least 2bones. Someboneshave
several protective factors; both radius andanklehad3protec-
tive factors. A total of 12 bones had at least 1 protective factor.
Smoking was not identified as a major risk factor in this
study (Tables 4 and 5). However, our data included only diag-
nosedpast or current smoking,whichmost reliablymaymean
that someone was offered smoking cessation therapy. Thus,
our count of smokers is likely an underestimate. Only 10.2%
of patients were coded as past or current smokers (Table 1),
whereas 18%of the general population is expected to smoke12
and other nonunion cohort studies have reported a preva-
lence of smoking higher than the US average.13 Similarly, we
mayunderestimateobesityprevalence;onlydiagnosedobesity
Table 2. Demographic Summary of AdultsWith Fracture and Comorbid Condition
Risk Factor
No. (%) OR (95% CI)
P ValueFractures Normal Healing Nonunion Fracture Univariate Multivariate
Male gender 130 378 (42.1) 123 368 7010 1.18 (1.14-1.21) 1.21 (1.16-1.25) ≤.001
Cardiovascular diseasea 96 209 (31.1) 90 221 5988 1.46 (1.41-1.51) 0.94 (0.90-0.98) ≤.05
Allergya 60 386 (19.5) 57 310 3076 1.04 (1.00-1.08) 0.90 (0.86-0.93) ≤.001
Osteoarthritis only 42 928 (13.9) 39 418 3510 1.96 (1.89-2.04) 1.45 (1.39-1.52) ≤.001
Past or current smoker 31 610 (10.2) 29 297 2313 1.62 (1.54-1.69) 1.20 (1.14-1.26) ≤.001
Obesity 23 719 (7.7) 21 882 1837 1.70 (1.62-1.79) 1.19 (1.12-1.25) ≤.001
Type 2 diabetes 23 681 (7.7) 21 958 1723 1.60 (1.52-1.68) 1.15 (1.07-1.24) ≤.001
Renal insufficiency 19 255 (6.2) 17 678 1577 1.80 (1.71-1.90) 1.11 (1.04-1.17) ≤.001
Vitamin D deficiency 12 661 (4.1) 11 796 865 1.44 (1.34-1.54) 1.14 (1.05-1.22) ≤.001
Osteoporosis 11 683 (3.8) 10 774 909 1.67 (1.55-1.78) 1.24 (1.14-1.34) ≤.001
Nutritional deficiency 7282 (2.4) 6612 670 2.00 (1.84-2.16) 1.09 (1.00-1.19) .05
Alcoholism 5616 (1.8) 5198 418 1.57 (1.42-1.73) 1.05 (0.94-1.17) .36
Type 1 diabetes 3194 (1) 2856 338 2.42 (2.16-2.71) 1.40 (1.21-1.61) ≤.001
Phlebitis 3100 (1) 2786 314 2.20 (1.96-2.47) 1.10 (0.97-1.24) .15
Osteoarthritis and rheumatoid
arthritis
2668 (0.9) 2396 272 2.51 (2.21-2.84) 1.58 (1.38-1.82) ≤.001
Rheumatoid arthritis 1920 (0.6) 1804 116 1.42 (1.17-1.71) 1.14 (0.93-1.38) .20
Abbreviation: OR, odds ratio.
a Protective factor.
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was analyzed, so many people with nonunion fractures may
have been obese but we have no record of it.
Lack of convergence of the model was a rare problem
(Tables4and5)except forcoagulants,whichappear toberarely
used among patients with fractures (Table 3). The number of
patients withmultiple scaphoid fracturesmay have been too
small to find a solution for nonunion associated with mul-
tiple fractures. Only 10 bone–risk factor ORs other than co-
agulants could not be estimated.
Discussion
There were clear demographic differences between patients
whose fractureshealedandthosewhose fractures failed toheal
(Table 1). Most risk factors conferred a relatively small in-
crease in multivariate nonunion risk (Table 2), perhaps be-
cause there are complex interactions betweenandamong risk
factors. Use of certain medications was an important deter-
minantofnonunion (Table 3).Adjustingmedicationusebypa-
tients may enable physicians to improve the odds that a pa-
tient will heal. Nonunion rates varied among bones, and the
contributions of various risk factors showed a complex inter-
play (Tables 4 and 5). In general, nonunion rate appears to be
a function of fracture severity, fracture location, disease co-
morbidity, and medication use.
The distinction between univariate andmultivariate ORs
is important. For example, type2diabeteswasassociatedwith
a univariate OR of 1.60 and amultivariate OR of 1.15 (Table 2).
If that diagnosis is the only information that a clinician has
about a patient, then it is reasonable to conclude that this pa-
tient has a 1.60-fold higher risk of nonunion than does a per-
sonwithout type2diabetes.Asothervariablesbecomeknown
and can be incorporated into a risk assessment, the risk asso-
ciated specifically with type 2 diabetes decreases. In amulti-
variateanalysis,whichcontrols formanyother factors, thenon-
union risk associatedwith type 2 diabeteswas 1.15-fold times
the riskofnonunion inapersonwithout thatdisease (Table 2).
It is almost certainly the case that type2diabeteshasnot been
diagnosed and treatment has not been instituted in some pa-
tients; thus, the diseasewould not have been analyzed in this
study. Diabetesmedications other than insulin appear to pro-
vide protection fromnonunion (Tables 4 and 5), although the
mechanism of such a protective effect is not known. When
working with large patient databases (eg, big data), unantici-
pated associations are likely to be found. Causality cannot be
testedwithoutusinganexperimental approach; therefore, big
dataprojects shouldbe regardedasanopportunity forhypoth-
esis generation rather than hypothesis testing.
The overall nonunion rate that we report was 4.9%
(Table 1). This rate is somewhat lower than others reported in
the literature,1,2 although thehealing rate for individual bones
aligns well with previously published information. For ex-
ample, the tibial nonunion ratewe reportwas 7.4% for 12 808
fractures. The literature suggests that the expected non-
union rate for tibial fractures is 7.6%, a value derived by col-
lating the reportedhealing rate in46publications spanning the
period from1976 to2014and including5920 fractures treated
Table 3. Medication Use by AdultsWith Fracture
Risk Factor
No. (%) OR (95% CI)
P ValueFractures
Normal
Healing
Nonunion
Fracture Univariate Multivariate
Antibiotics 201 728 (65.2) 190 592 11 136 1.47 (1.42-1.52) 1.17 (1.13-1.21) ≤.001
Analgesics (NSAIDs and opioids) 129 213 (41.8) 120 703 8510 2.70 (2.56-2.85) 1.84 (1.73-1.95) ≤.001
Menopausal corticosteroids 102 711 (33.2) 97 001 5710 1.22 (1.18-1.25) 1.02 (0.98-1.05) .40
Opioids 98 267 (31.8) 93 663 4604 1.88 (1.78-2.00) 1.43 (1.34-1.52) ≤.001
Cardiac medications 91 942 (29.7) 86 415 5527 1.37 (1.32-1.41) 1.04 (0.99-1.08) .13
Diuretics 38 947 (12.6) 36 257 2690 1.52 (1.46-1.59) 1.13 (1.07-1.18) ≤.001
Anticonvulsants 34 859 (11.3) 31 928 2931 2.04 (1.96-2.12) 1.37 (1.31-1.43) ≤.001
Antidiabeticsa,b 25 319 (8.2) 23 692 1627 1.36 (1.29-1.43) 0.92 (0.86-0.99) ≤.001
Anticoagulants 24 693 (8) 21 841 2852 2.87 (2.75-2.99) 1.58 (1.51-1.66) ≤.001
NSAIDs 23 847 (7.7) 23 186 661 1.09 (1.00-1.19) 0.98 (0.89-1.07) .60
Oral contraceptivesb 19 989 (6.5) 19 227 762 0.75 (0.70-0.81) 0.88 (0.81-0.95) ≤.001
Osteoporosis medications 16 771 (5.4) 15 658 1113 1.40 (1.31-1.49) 1.17 (1.08-1.26) ≤.001
Nonmenopausal corticosteroids 12 765 (4.1) 12 004 761 1.23 (1.15-1.33) 1.07 (0.99-1.15) .09
Insulin 12 412 (4) 11 347 1065 1.87 (1.75-1.99) 1.21 (1.10-1.31) ≤.001
Benzodiazepines only 9118 (3) 8565 553 1.43 (1.31-1.56) 1.20 (1.10-1.31) ≤.001
Anticonvulsants and benzodiazepines 7154 (2.3) 6509 645 2.20 (2.03-2.39) 1.49 (1.36-1.62) ≤.001
Immunosuppressants 4076 (1.3) 3781 295 1.51 (1.34-1.70) 1.10 (0.97-1.25) .14
Parathyroid hormone 861 (0.3) 781 80 1.98 (1.57-2.49) 1.27 (0.99-1.62) .06
Coagulants 318 (0.1) 314 4 0.25 (0.09-0.66) 0.24 (0.09-0.64) .004
Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs; OR, odds ratio.
a Not insulin.
b Protective factor.
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withavarietyof conservative andoperativemethods.14-58The
agreement betweenour database and the literature is striking
sincebothsamples includemanypatientswhoreceivedawide
range of treatments.
Similarly, the nonunion rate we report for clavicle frac-
tures is 8.2% for 7414 fractures. Collation of literature on
clavicle fractures suggests that the expected nonunion rate is
8.6%. This percentagewas derived from the reported healing
rate in 12 separate publications59-70 spanning the period from
2004 to 2013 and including 3168patients treatedwith a range
ofconservativeandoperativemethods.Bothsamplesare large,
and thenonunionrate inourdatabaseagaindiffersby less than
a percentage point from the literature values.
Theoverallnonunionratewereport (4.9%) is slightly lower
than the 5% to 10% that reviews suggest,1,2 whichmay reflect
reporting bias. Clinicians generally report more often on frac-
tures that heal poorly.71 Metacarpal fractures heal with a non-
union rate of just 1.5% and have been reported only 226 times
in the literature (perPubMedsearch,December21,2015: search
terms,bone fracturehealingandmetacarpal). Conversely, tibia
fractureshaveanonunion rateof 7.4%andhavebeen reported
2578 times in the literature (per PubMed search,December 21,
2015: search terms, bone fracture healing and tibia). Similarly,
femur fractures have a nonunion rate of 13.9% and have been
reported 2791 times in the literature (per PubMed search, De-
cember21,2015, searchterms,bone fracturehealingand femur).
This research has several limitations. First, TruvenHealth
Analytics is a payer database that excludes unemployed or in-
digent patientswhomighthavehadahigher rate of nonunion.
Second, some diagnoses may have been coded incorrectly as
fracture if codingwas performedbefore radiographic imaging.
However, this error isunlikelybecause rule-out codeswerenot
counted; such codes are used to order imaging if a fracture is
suspected.Third,somefractures that receivedtreatment in2011
couldhaveoccurredearlier. Fourth, uncodedpatientdata can-
notcontribute toconclusions.Dataweremore likely tobemiss-
ing from the database if information was not crucial to reim-
bursement; smokers not receiving medication for smoking
cessationwould likely not be coded as smokers. Nevertheless,
missing data are a problem in every study, including random-
ized clinical trials. Therefore, we used statistical methods, in-
cluding randomforest analysis, that are robustandresilientde-
spitemissingdata.11 Additional limitationsare characteristic of
claims databases in general; there is imprecision in ICD-9 cod-
ing schemes,72 and coding errors are common but are as-
sumedtodistribute randomlyand tobeminimizedby theneed
for accurate reporting for claims reimbursement and by legal
penalties for fraudulent reporting.73 Limitationsdonot appear
to be a substantial issue because the nonunion rateswe report
are similar to others in the literature.
An important strength of this research is that it has con-
tributednovel insights into thecauseof fracturenonunion.For
example,useof certainmedications is akey risk factor for frac-
ture nonunion (Table 3). Becausemedication use is a modifi-
able risk factor, our findings suggest that clinicianscouldcoun-
sel patients about use of medications. Other strengths of this
research are that all datawere collected prospectively, the 12-
month follow-up time represents a longer follow-up intervalTa
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Table 5. Multivariate ORs for Nonunion Among AdultsWith Fracture: Second Set
Risk Factor
OR (95% CI)
Ulna
(n = 8605)
Clavicle
(n = 7414)
Scaphoid
(n = 7149)
Patella
(n = 6710)
Pelvis
(n = 6356)
Fibula
(n = 5978)
Neck
of Femur
(n = 5321)
Tibia
and Fibula
(n = 5249)
Femur
(n = 5022)
≥6 vs 1-2 Fractures
per patient
1.22
(0.62-2.39)
0.21
(0.03-1.58)
NC 0.90
(0.33-2.41)
3.94
(2.61-5.96)a
1.92
(0.78-4.73)
2.59
(1.43-4.69)b
2.33
(1.41-3.85)a
2.11
(1.45-3.07)a
NSAID with opioid
use vs no analgesics
2.47
(1.68-3.63)a
1.95
(1.39-2.75)a
2.59
(2.09-3.22)a
1.94
(1.00-3.78)
1.30
(0.82-2.07)
1.40
(0.88-2.25)
1.54
(1.03-2.29)
1.41
(1.01-1.96)
1.61
(1.14-2.26)c
Requires operative
vs conservative
procedure
1.66
(1.31-2.12)a
2.17
(1.71-2.74)a
1.40
(1.15-1.69)a
4.20
(2.44-7.21)a
1.95
(1.31-2.89)a
2.05
(1.41-2.97)a
1.32
(0.58-2.95)
1.39
(1.05-1.85)
4.61
(2.30-9.22)a
Open vs closed
fracture
1.16
(0.85-1.59)
1.23
(0.70-2.16)
1.61
(1.05-2.46)
1.34
(0.85-2.09)
0.99
(0.55-1.76)
1.83
(1.16-2.88)c
1.31
(0.88-1.94)
2.04
(1.69-2.46)a
1.79
(1.43-2.24)a
Anticoagulant use
vs none
1.77
(1.24-2.52)b
0.85
(0.54-1.35)
1.29
(0.80-2.10)
2.04
(1.42-2.92)a
1.35
(1.05-1.74)
2.50
(1.81-3.43)a
1.62
(1.32-2.00)a
1.69
(1.41-2.02)a
1.43
(1.19-1.72)a
Osteoarthritis with
rheumatoid arthritis
vs no diagnosis
1.38
(0.52-3.66)
0.70
(0.15-3.20)
2.48
(0.90-6.84)
1.90
(0.73-4.96)
1.80
(0.73-4.43)
0.51
(0.11-2.38)
2.00
(1.12-3.56)
1.11
(0.38-3.26)
0.57
(0.30-1.09)
Anticonvulsants
with
benzodiazepines
vs none
1.10
(0.63-1.91)
0.86
(0.46-1.60)
1.02
(0.59-1.74)
3.32
(1.82-6.04)a
1.86
(1.15-3.01)
1.31
(0.66-2.62)
1.49
(0.98-2.26)
0.62
(0.33-1.14)
1.93
(1.27-2.92)b
Unknown energy
vs low-energy
accident
1.31
(0.97-1.75)
1.24
(0.90-1.69)
2.37
(1.73-3.24)a
1.62
(0.98-2.67)
2.57
(1.43-4.60)b
1.07
(0.73-1.56)
1.50
(1.11-2.01)c
1.43
(1.08-1.87)
1.26
(0.90-1.76)
Osteoarthritis only
vs no diagnosis
1.52
(1.15-2.00)b
0.99
(0.74-1.31)
2.20
(1.74-2.78)a
2.44
(1.68-3.54)a
1.53
(1.15-2.02)b
1.36
(0.96-1.92)
1.56
(1.22-1.99)a
1.02
(0.79-1.30)
0.91
(0.73-1.13)
Opioids only vs
no opioids
2.00
(1.36-2.94)a
1.47
(1.04-2.06)
3.14
(2.56-3.85)a
1.03
(0.51-2.06)
1.06
(0.66-1.69)
1.10
(0.69-1.77)
0.89
(0.59-1.33)
1.02
(0.73-1.41)
0.99
(0.70-1.40)
Type 1 diabetes
vs no diagnosis
0.46
(0.13-1.70)
1.76
(0.56-5.48)
1.43
(0.44-4.65)
0.20
(0.02-1.67)
0.59
(0.16-2.11)
0.85
(0.21-3.47)
2.01
(1.03-3.92)
2.47
(1.27-4.80)c
1.17
(0.59-2.30)
High-energy vs
low-energy accident
1.12
(0.73-1.69)
0.83
(0.57-1.21)
0.85
(0.51-1.41)
2.18
(1.10-4.32)
1.73
(0.93-3.19)
1.42
(0.83-2.42)
1.62
(1.07-2.44)
1.34
(0.97-1.85)
1.38
(0.94-2.03)
Anticonvulsants
only vs none
1.28
(0.96-1.69)
1.39
(1.06-1.82)
0.99
(0.74-1.31)
1.41
(0.94-2.10)
1.68
(1.29-2.19)a
1.69
(1.20-2.37)b
0.98
(0.76-1.26)
1.20
(0.97-1.49)
1.51
(1.22-1.86)a
3-5 vs 1-2
Fractures per
patient
1.00
(0.72-1.39)
0.99
(0.65-1.50)
0.36
(0.18-0.73)d,e
1.78
(1.01-3.12)
1.66
(1.24-2.22)a
1.25
(0.80-1.94)
1.25
(0.91-1.72)
0.90
(0.71-1.13)
1.40
(1.09-1.78)c
Osteoporosis vs
no diagnosis
0.78
(0.44-1.39)
1.30
(0.73-2.29)
2.45
(1.31-4.58)b
2.82
(1.53-5.17)a
1.44
(0.86-2.41)
0.32
(0.11-0.96)
1.09
(0.78-1.50)
0.60
(0.36-1.01)
1.58
(1.13-2.20)c
Male vs female
gender
1.12
(0.90-1.38)
0.61
(0.50-0.74)a,e
2.55
(2.09-3.11)a
1.56
(1.11-2.20)
1.09
(0.85-1.40)
0.95
(0.72-1.26)
1.21
(0.96-1.50)
1.22
(1.02-1.46)
0.97
(0.81-1.17)
Insulin use vs none 1.38
(0.76-2.50)
0.82
(0.39-1.72)
0.76
(0.35-1.62)
1.30
(0.64-2.63)
1.13
(0.63-2.03)
1.17
(0.59-2.33)
0.92
(0.59-1.42)
0.87
(0.55-1.35)
1.20
(0.80-1.80)
Past/current smoker
vs never smoked
1.36
(1.02-1.81)
1.36
(1.05-1.77)
1.11
(0.86-1.43)
1.22
(0.79-1.86)
1.38
(1.02-1.87)
1.67
(1.17-2.37)b
1.01
(0.75-1.35)
1.33
(1.06-1.68)
1.45
(1.14-1.84)b
Benzodiazepine
only vs no
anticonvulsants
1.18
(0.71-1.95)
1.48
(0.95-2.30)
0.98
(0.62-1.53)
2.42
(1.23-4.77)
1.89
(1.11-3.22)
0.87
(0.39-1.91)
0.62
(0.32-1.21)
1.28
(0.78-2.09)
1.41
(0.88-2.25)
Obesity vs no
diagnosis
1.66
(1.18-2.31)
b
1.57
(1.05-2.34)
0.98
(0.68-1.41)
1.20
(0.75-1.92)
1.34
(0.93-1.94)
0.85
(0.56-1.30)
1.61
(1.18-2.21)b
1.20
(0.90-1.60)
1.11
(0.85-1.45)
Antibiotic use
vs none
1.22
(0.97-1.51)
1.07
(0.88-1.28)
1.04
(0.89-1.20)
1.15
(0.79-1.67)
1.18
(0.91-1.52)
1.02
(0.76-1.37)
1.25
(0.98-1.58)
1.34
(1.11-1.61)b
1.32
(1.08-1.60)c
Osteoporosis
medication use
vs none
1.43
(0.90-2.26)
0.66
(0.38-1.15)
0.66
(0.30-1.45)
0.68
(0.33-1.37)
1.12
(0.68-1.83)
1.16
(0.57-2.39)
1.23
(0.90-1.66)
1.36
(0.85-2.14)
0.91
(0.65-1.28)
Type 2 diabetes
only vs no diagnosis
0.65
(0.39-1.08)
0.83
(0.49-1.41)
0.61
(0.35-1.08)
1.22
(0.65-2.29)
1.02
(0.64-1.61)
1.08
(0.62-1.86)
1.14
(0.78-1.66)
1.38
(0.97-1.96)
1.30
(0.91-1.85)
Vitamin D deficiency
vs no diagnosis
1.03
(0.64-1.66)
1.29
(0.82-2.01)
0.94
(0.54-1.65)
1.49
(0.82-2.70)
0.98
(0.60-1.60)
1.00
(0.54-1.86)
1.32
(0.91-1.91)
1.09
(0.73-1.65)
2.15
(1.56-2.96)a
Diuretic use vs none 0.88
(0.64-1.20)
0.98
(0.70-1.36)
0.89
(0.63-1.27)
1.26
(0.82-1.93)
1.18
(0.85-1.63)
1.40
(0.98-2.00)
1.06
(0.82-1.37)
1.14
(0.88-1.48)
1.20
(0.94-1.52)
Renal insufficiency
vs no diagnosis
1.59
(1.13-2.24)
1.20
(0.81-1.78)
0.90
(0.62-1.30)
1.28
(0.78-2.11)
1.25
(0.90-1.75)
0.98
(0.59-1.63)
0.74
(0.53-1.01)
1.13
(0.82-1.53)
1.00
(0.76-1.31)
Immunosuppressant
use vs none
1.50
(0.72-3.09)
0.43
(0.13-1.43)
0.57
(0.19-1.66)
4.83
(2.11-11.08)a
1.10
(0.44-2.74)
2.07
(0.81-5.32)
0.84
(0.42-1.66)
1.25
(0.64-2.47)
1.08
(0.52-2.24)
Alcoholism vs no
diagnosis
1.43
(0.87-2.34)
0.99
(0.58-1.66)
0.93
(0.47-1.83)
1.36
(0.57-3.25)
0.84
(0.47-1.50)
0.73
(0.30-1.75)
0.85
(0.51-1.40)
0.63
(0.37-1.04)
0.60
(0.35-1.03)
(continued)
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than used in most other published studies,5 and the out-
comes reported reflect real-world outcomes.
Conclusions
Fracture nonunion can result from the interplay of many
risk factors. Key risk factors include features of the fracture,
such as severity and location, as well as issues such as
comorbidities and use of certain medications. Fracture
severity, fracture location, comorbidity, and medication use
could be incorporated into an algorithm that would help cli-
nicians determine which fractures are at greatest risk of
nonunion. Medications have a significant effect on fracture
healing and can potentially be altered after fracture to
improve healing.
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Table 5. Multivariate ORs for Nonunion Among AdultsWith Fracture: Second Set (continued)
Risk Factor
OR (95% CI)
Ulna
(n = 8605)
Clavicle
(n = 7414)
Scaphoid
(n = 7149)
Patella
(n = 6710)
Pelvis
(n = 6356)
Fibula
(n = 5978)
Neck
of Femur
(n = 5321)
Tibia
and Fibula
(n = 5249)
Femur
(n = 5022)
Phlebitis vs no
diagnosis
1.69
(0.76-3.73)
0.67
(0.25-1.80)
0.67
(0.22-1.99)
0.32
(0.07-1.38)
0.77
(0.39-1.54)
0.93
(0.43-2.01)
1.78
(1.08-2.92)
1.12
(0.68-1.84)
2.22
(1.41-3.49)a
Parathyroid
hormone use vs no
hormones
NC 2.59
(0.63-10.66)
NC NC 0.42
(0.09-1.86)
10.1
(2.10-48.43)b
0.34
(0.08-1.47)
1.42
(0.39-5.21)
2.17
(0.81-5.86)
Rheumatoid
arthritis only vs no
diagnosis
0.80
(0.23-2.75)
3.89
(1.59-9.51)b
0.80
(0.18-3.62)
NC 0.63
(0.08-4.75)
0.35
(0.04-2.87)
1.11
(0.33-3.75)
1.78
(0.73-4.37)
1.24
(0.46-3.31)
Nonmenopausal
corticosteroid use vs
none
0.98
(0.62-1.55)
0.68
(0.40-1.13)
1.07
(0.72-1.59)
0.45
(0.18-1.11)
1.40
(0.90-2.18)
1.25
(0.70-2.23)
1.63
(1.06-2.50)
1.02
(0.68-1.54)
1.30
(0.88-1.92)
Cardiac medication
use vs none
1.04
(0.80-1.35)
1.03
(0.81-1.32)
0.97
(0.74-1.25)
1.20
(0.82-1.77)
1.07
(0.81-1.43)
1.05
(0.76-1.46)
1.12
(0.88-1.42)
1.00
(0.80-1.23)
1.10
(0.88-1.36)
Nutritional
deficiency vs no
diagnosis
1.33
(0.77-2.27)
0.72
(0.37-1.39)
0.55
(0.25-1.24)
0.82
(0.35-1.92)
1.39
(0.93-2.05)
0.86
(0.39-1.90)
1.10
(0.76-1.60)
0.85
(0.56-1.30)
0.81
(0.56-1.17)
Menopausal
corticosteroid use vs
none
1.03
(0.83-1.27)
1.22
(1.00-1.48)
0.89
(0.75-1.05)
0.94
(0.67-1.31)
0.89
(0.69-1.15)
1.13
(0.85-1.51)
0.90
(0.73-1.12)
1.01
(0.83-1.22)
0.82
(0.67-0.99)
NSAIDs only vs no
analgesics
1.00
(0.51-1.95)
0.75
(0.36-1.57)
1.09
(0.76-1.57)
0.92
(0.31-2.71)
0.66
(0.29-1.49)
1.15
(0.56-2.34)
0.55
(0.27-1.13)
0.96
(0.54-1.70)
0.98
(0.55-1.72)
Coagulant use vs
none
NC NC NC NC NC NC NC NC NC
Medicare vs
commercial payer
0.73
(0.17-3.19)
NC 1.23
(0.27-5.61)
NC 0.88
(0.19-3.96)
0.56
(0.07-4.37)
0.61
(0.24-1.54)
1.52
(0.61-3.78)
0.53
(0.22-1.29)
Oral contraceptive
use vs none
1.04
(0.69-1.58)
1.29
(0.85-1.94)
0.80
(0.54-1.19)
1.16
(0.54-2.47)
0.83
(0.47-1.45)
0.97
(0.52-1.80)
1.27
(0.74-2.16)
1.19
(0.80-1.77)
0.67
(0.41-1.11)
Allergy vs no
diagnosis
0.83
(0.64-1.06)
0.94
(0.75-1.18)
0.97
(0.80-1.17)
0.83
(0.56-1.23)
1.00
(0.74-1.35)
0.94
(0.67-1.30)
0.84
(0.64-1.10)
0.70
(0.55-0.89)d
0.69
(0.54-0.87)d,e
Treatment
information
unknown vs
conservative
0.96
(0.75-1.21)
1.25
(0.97-1.59)
0.85
(0.73-0.99)
1.24
(0.74-2.07)
1.37
(0.96-1.96)
1.51
(1.10-2.06)c
1.01
(0.45-2.28)
0.87
(0.65-1.16)
3.52
(1.77-7.01)a
Antidiabetics, not
insulin vs no
antidiabetics
0.90
(0.56-1.44)
0.97
(0.58-1.63)
1.25
(0.76-2.05)
0.86
(0.46-1.61)
1.09
(0.68-1.77)
0.68
(0.39-1.18)
0.94
(0.65-1.36)
0.90
(0.63-1.27)
0.76
(0.53-1.08)
Medicaid vs
commercial payer
0.82
(0.58-1.16)
1.01
(0.71-1.43)
0.86
(0.63-1.19)
1.35
(0.86-2.11)
1.15
(0.84-1.58)
0.91
(0.58-1.41)
0.84
(0.61-1.15)
1.16
(0.90-1.50)
0.77
(0.60-0.99)
Cardiovascular
disease vs no
diagnosis
1.06
(0.82-1.38)
1.06
(0.83-1.34)
0.80
(0.62-1.02)
0.79
(0.52-1.18)
0.78
(0.58-1.05)
1.22
(0.87-1.71)
0.78
(0.60-1.02)
1.00
(0.80-1.24)
0.88
(0.70-1.10)
Patient age increase
by 10 y
0.89
(0.82-0.96)d,e
1.23
(1.15-1.32)a
0.80
(0.75-0.85)a,e
0.85
(0.74-0.97)
1.05
(0.95-1.15)
0.96
(0.86-1.08)
0.94
(0.85-1.03)
1.02
(0.95-1.09)
1.01
(0.94-1.08)
Abbreviations: NC, nonconvergence; NSAID, nonsteroidal anti-inflammatory
drug; OR, odds ratio.
a P  .001.
bP  .005.
c P  .01.
dP  .05.
e Protective factor.
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